Established in Hangzhou
Westlake Omics was founded in July 2020 to connect proteomics, AI and biomedical applications.
Company
Proteomics, AI and diagnostics.
One connected company.
Founded in Hangzhou in 2020, Westlake Omics brings together AI virtual cells, proteomics research services and clinical diagnostic technologies.
Company history
From protein measurements
to predictive biology.
Expanding the experimental foundation
Research and clinical translation capabilities developed to support molecular diagnostics and pharmaceutical investigation.
Spatial proteomics research
Collaborative FAXP research published in Nature Communications adds tissue, cell and organelle context to protein measurement.
Protein-rich virtual cells
Proteomics-rich AIVC becomes a core scientific direction, alongside established research services and clinical products. Collaborative ProteinTalks research is published in Nature.
Company history · Company announcement · 2022 · FAXP research · ProteinTalks research
Institutional support
Publicly announced backers
Our public company announcements have named investors across life sciences, technology and industrial healthcare.
CD Capital
Gaorong Capital
GL Ventures
Efung Capital
Med-Fine Capital
Westlake Science VC
Rivercity Kindstar Fund
Selected institutions named in public announcements, 2021–2026. Corporate materials · Announcement · 2021 · Announcement · 2026
Our portfolio
Platforms, services and clinical products.
AIVC
Purpose-designed protein-state data, multimodal models and independent drug-research evaluation.
AI virtual cellsResearch services
Quantitative proteomics, spatial analysis, plasma enrichment, multi-omics and bioinformatics.
Browse servicesClinical diagnostics
Laboratory measurement and translational proteomics, including LMDx IGF-I and ThyroProt.
Clinical applicationsResearch partnerships
Contact Westlake Omics.
Connect with the right team for research, technology and diagnostic enquiries.